Royalty Pharma plc (RPRX) To Go Ex-Dividend on November 15th

Royalty Pharma plc (NASDAQ:RPRX) announced a quarterly dividend on Friday, October 11th, Zacks reports. Shareholders of record on Friday, November 15th will be given a dividend of 0.21 per share by the biopharmaceutical company on Tuesday, December 10th. This represents a $0.84 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend is Friday, November 15th.

Royalty Pharma has increased its dividend payment by an average of 38.7% annually over the last three years. Royalty Pharma has a payout ratio of 19.1% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Royalty Pharma to earn $4.33 per share next year, which means the company should continue to be able to cover its $0.84 annual dividend with an expected future payout ratio of 19.4%.

Royalty Pharma Trading Up 1.9 %

NASDAQ RPRX opened at $28.02 on Friday. The firm’s fifty day moving average price is $27.86 and its 200 day moving average price is $27.75. Royalty Pharma has a 12 month low of $25.20 and a 12 month high of $31.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. The company has a market capitalization of $16.63 billion, a price-to-earnings ratio of 24.80, a price-to-earnings-growth ratio of 4.06 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. During the same quarter last year, the company posted $0.85 earnings per share. On average, sell-side analysts expect that Royalty Pharma will post 4.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on RPRX. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley lifted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Finally, The Goldman Sachs Group increased their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Royalty Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.